Entrada Therapeutics Inc (TRDA) Annual Income Statement (USD)
TRDA Quarterly Financials (USD)
Frequently Asked Questions About Entrada Therapeutics Inc (TRDA) Stock
Entrada Therapeutics Inc's (TRDA) last reported annual revenue was USD 129.01 Million.
Entrada Therapeutics Inc's (TRDA) annual revenue growth rate based on the revenue reported in the past 5 years is : 14.26%
Entrada Therapeutics Inc's(TRDA) is not profitable as of its last reported annual financials.
The net profit margin for Entrada Therapeutics Inc's(TRDA) from its laster reported year is -5.18%
The return on equity (ROE) for Entrada Therapeutics Inc's(TRDA) from its last reported annual financials is : 32.80%
The return on assets (ROA) for Entrada Therapeutics Inc's(TRDA) from its last reported annual financials is : 10.86%
The return on invested capital (ROIC) for Entrada Therapeutics Inc's(TRDA) from its last reported annual financials is : -9.63%
The Debt to Equity ratio for Entrada Therapeutics Inc's(TRDA) from its last reported annual financials is : 0.00%
The dividend yield for Entrada Therapeutics Inc's(TRDA) from its laster reported year is 0.00%
Entrada Therapeutics Inc's(TRDA) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TRDA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
